Answers are grounded in this paper and cite their sources.
Real-world evidence shows safety of high-frequency remote electrical neuromodulation for migraine treatment, suggesting broad acceptability for patients.
Introduction: Remote electrical neuromodu‑ lation (REN) is an FDA-cleared, nonsignifcan risk, drug-free, prescribed wearable device (Nerivio®) for the acute treatment of migraine and/or every other day for prophylactic treat‑ ment in patients aged 8 years and older. Despite established effcacy within labeled use param‑ eters, some patients adopt more frequent treat‑ ment regimens, including multiple treatments within a single day, daily use, or both. This study assessed the safety and tolerability of REN when used at frequencies exceeding the labeled indication.
No takes yet. Share an insight, caveat, or question.
Rastogi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: